Editas Medicine Announces New EDIT-301 Safety and Efficacy D

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

San Diego , California , United States , Cambridge , Cambridgeshire , United Kingdom , San Diego Convention Center , American , Rabi Hanna , Baisong Mei , Cristi Barnett , Department Of Pediatric Hematology Oncology , Harvard University Cas , Broad Institute Cas , Globenewswire Inc , American Society Of Hematology , Nasdaq , Broad Institute , Editas Medicine Inc , Exchange Commission , Division Of Pediatric Hematology Oncology , European Hematology Association , Hematology Association , Annual Congress , Annual Meeting , Senior Vice President , Chief Medical Officer , Pediatric Hematology Oncology , Marrow Transplantation , Cleveland Clinic Children , Severe Sickle Cell , Transfusion Dependent Beta , Presentation Details , Gene Editing , Sustained Normalization , Increased Fetal Hemoglobin , Severe Sickle Cell Disease , Transfusion Dependent Beta Thalassemia , Diego Convention Center , Harvard University , Private Securities Litigation Reform Act , Annual Report , Investor Contact ,